ESTA

Over the past six months, ESTA stock experienced several notable events: on August 6, 2026, Q2 2026 financial results showing 31.7% revenue growth but a loss led to a -13.37% stock price change; an announcement on July 23, 2026, regarding Q2 results caused a -2.95% change; the appointment of Taylor Harris to the Board on June 29, 2026, resulted in a -1.09% change; inclusion in the U.S. Small-Cap Russell 2000® Index on June 25, 2026, led to a +2.13% increase; Q1 2026 financial results on May 6, 2026, showed 45% overall revenue growth and 216% U.S. revenue rise but a wider loss per share, resulting in a +5.00% change; and the refinancing of its credit facility on April 30, 2026, led to a +9.93% increase. On September 21, 2026, the company presented new clinical and scientific data supporting Breast Tissue Preservation and expanded its minimally invasive product line, linking clinical milestones to its financial engine. However, on September 23, 2026, ESTA shares fell 3.5%, with the stock considered overvalued by GF Value, and insider selling of $36.9M worth of shares over the past year without any buying activity was noted. The stock's 52-week range was between $37.37 and $97.59, with a closing price of $68.72 on September 21, 2026.